Sex-specific regulation of cardiac microRNAs targeting mitochondrial proteins in pressure overload

ConclusionWe put forward that the male-specific induction of miRNAs and corresponding downregulation of downstream protein targets involved in mitochondrial metabolism may contribute to sex-specific remodeling in PO-induced LVH.
Source: Biology of Sex Differences - Category: Biology Source Type: research

Related Links:

ConclusionCongruence between physical and affective symptom clusters should be considered when identifying patients at higher risk for poor outcomes.
Source: Heart and Lung: The Journal of Acute and Critical Care - Category: Respiratory Medicine Source Type: research
Phase III VICTORIA study with vericiguat in patients with worsening chronic heart failure meets primary endpointVericiguat reduced the risk of cardiovascular death or heart failure hospitalization versus placebo when given in combination with available heart failure therapies / Vericiguat is the first-in-class soluble guanylate cyclase stimulator being developed to treat patients with worsening chronic heart failuremehr ...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news
Publication date: Available online 17 November 2019Source: Pharmacological ResearchAuthor(s): Qiujin Jia, Lirong Wang, Xiaonan Zhang, Yuejia Ding, Hao Li, Yingxi Yang, Ao Zhang, Yanyang Li, Shichao Lv, Junping ZhangAbstractIn recent years, although the concept and means of modern treatment of chronic heart failure(CHF) are continually improving, the readmission rate and mortality rate are still high. At present, there is evidence that there is a link between gut microbiota and heart failure, so the intervention of gut microbiota and its metabolites is expected to become a potential new therapeutic target in heart failure. ...
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research
Analysis of Medicare Part D and Medicaid data highlights increased use and favorable cost profiles for Entresto and Corlanor, two drugs approved in 2015 to treat heart failure.
Source: Health News - UPI.com - Category: Consumer Health News Source Type: news
Merck&Co Inc
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
Vericiguat reduced the risk of cardiovascular death or heart failure hospitalization versus placebo when given in combination with available heart failure therapies / Vericiguat is the first-in-class soluble guanylate cyclase stimulator being developed to treat patients with worsening chronic heart failure
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news
A new look at an old study helps clarify some of the mystery on the safe use of digoxin in heart failure.European Heart Journal
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
AbstractPulmonary hypertension (PH) is a complex and progressive disease characterized by increased pulmonary vascular resistance and pulmonary artery pressure, leading to pulmonary vascular remodeling, right heart failure, and ultimately death. Although several molecular pathways related to vascular remodeling have been reported, the mechanism behind this fatal disease with poor prognosis remains largely unclear. Long noncoding RNAs (lncRNAs) have been proven to be playing crucial roles in various biological processes, and emerging studies demonstrated lncRNAs as essential epigenetic modifiers involved in the onset and de...
Source: Heart Failure Reviews - Category: Cardiology Source Type: research
AbstractPurpose of ReviewTo provide insight into the role of urine biomarkers and electrolytes for the management of heart failure.Recent FindingsThe age-dependent decrease in glomerular filtration rate due to loss of functional nephrons occurs at a faster pace in heart failure, potentially exacerbated by episodes of acute kidney injury. Urine biomarkers have not convincingly demonstrated to improve detection of irreversible renal damage and predict long-term renal trajectories, compared with serial creatinine measurements. Recent data show that natriuresis and diuretic response track poorly with glomerular filtration, but...
Source: Current Heart Failure Reports - Category: Cardiology Source Type: research
A translational rat model of chronic heart failure was employed to examine the cardioprotective effect of fabomotizole hydrochloride. Fabomotizole therapy for 28 days (15 mg/kg/day intraperitoneally) restored inotropic function of the left ventricle and increased ejection fraction from 54 ±3 to 65±3% (p=0.001). The inotropic function returned to normal against the background of significantly reduced myocardial expression of angiotensin (p=0.01) and glucocorticoid (p=0.03) receptors and significant increased expression of sigma-1 receptors (p=0.04). Inhibition of abnormal expression of angiotensin and glucocor...
Source: Bulletin of Experimental Biology and Medicine - Category: Biology Source Type: research
More News: Biology | Cardiology | Estradiol | Heart | Heart Failure | Hormones